Status:
ENROLLING_BY_INVITATION
An AI Model Predicts the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: a Multicenter, Bidirectional Cohort Study
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborating Sponsors:
First Affiliated Hospital of Jinan University
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
Neoadjuvant chemotherapy is an important part of the systematic treatment of breast cancer, and it is of great clinical significance to predict the efficacy of neoadjuvant chemotherapy in early stage....
Detailed Description
This is a multicenter, bidirectional cohort study. Retrospective training cohort, retrospective validation cohort and prospective test cohort were designed. Data of patients treated in the North Ward...
Eligibility Criteria
Inclusion
- Women
- Pathological diagnosis of non-metastatic invasive breast cancer (stage II-III)
- At least 4 cycles of neoadjuvant chemotherapy
- Radical surgery was performed after neoadjuvant chemotherapy
- There are pathological images and reports of breast puncture specimens before neoadjuvant chemotherapy
- 'There are MRI images and reports of breast MRI within 2 weeks before neoadjuvant chemotherapy
- There are standard clinical records
Exclusion
- Inflammatory breast cancer
- Bilateral breast cancer
- Newly diagnosed stage IV breast cancer
- Other tumors have not been completely removed or less than 3 years after surgery
- Treatment other than neoadjuvant therapy had been performed before surgery
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
840 Patients enrolled
Trial Details
Trial ID
NCT06510127
Start Date
August 1 2024
End Date
January 31 2026
Last Update
July 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China